The Discovery Trial for IgAN, MN, LN, and C3G Patients
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
Trial for people with
Primary Membranous Nephropathy (MN), IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G)
To determine if APL-2 can cause a reduction of proteinuria in patients with IgAN, C3G, or MN.
What is involved for the Patient?
Patients will be involved in the study for 16 weeks, and will take the study drug as a daily subcutaneous injection.
About the drug or intervention
APL-2 is a C3 complement mediator administered as daily subcutaneous infusions.
- Study CoordinatorFederico Grossi, MD, PhD
- Study Coordinator Emailclinicaltrials@apellis.com
- Study Coordinator Phone617-977-5717
- Site NameApellis Investigational Site
- SponsorApellis Pharmaceuticals, Inc.
- Study DrugAPL-2
- Estimated enrollment48
- Estimated end dateOctober, 2019